This is a slow-growing form of B-cell lymphoma. About 20% to 30% of all non-Hodgkin's lymphomas are follicular lymphoma (FL). This cancer usually starts in people who are over 65. It usually grows ...
FDA grants fast track designation to azer-cel, an allogeneic CAR T-cell therapy, for relapsed or refractory diffuse large ...
The EC approved the CAR T-cell therapy based on data from a Phase II study showing a 94 percent complete response rate.
Wojciech Jurczak, MD, PhD, ​​discusses the future of B-cell lymphoma therapy, with a focus on Bruton's tyrosine kinase ...
Chugai introduces Lunsumio for intravenous infusion, a bispecific antibody to treat relapsed or refractory follicular lymphoma in Japan: Tokyo Thursday, March 20, 2025, 11:00 Hrs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback